Treatment of melanoma cells with a bcl-2/bcl-xL antisense oligonucleotide induces antiangiogenic activity (Q40615175)

22 September 2017

Treatment of melanoma cells with a bcl-2/bcl-xL antisense oligonucleotide induces antiangiogenic activity (English)

1 reference

22 September 2017

angiogenesis inhibitor

1 reference

Daniela Trisciuoglio

2

0 references

Donatella Del Bufalo

object named as

Donatella Del Bufalo

1

0 references

author name string

Marco Scarsella

3

1 reference

22 September 2017

Uwe Zangemeister-Wittke

4

1 reference

22 September 2017

Gabriella Zupi

5

1 reference

22 September 2017

language of work or name

English

0 references

publication date

1 November 2003

1 reference

22 September 2017

1 reference

22 September 2017

22

1 reference

22 September 2017

52

1 reference

22 September 2017

8441-8447

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.onc.1206999

22 September 2017

0 references

cites work

Angiogenesis modulation in cancer research: novel clinical approaches

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206999

Lonidamine induces apoptosis in drug-resistant cells independently of the p53 gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206999

Bcl-2 overexpression decreases BCNU sensitivity of a human glioblastoma line through enhancement of catalase activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206999

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206999

Angiogenic potential of prostate carcinoma cells overexpressing bcl-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206999

Activity of a novel bcl-2/bcl-xL-bispecific antisense oligonucleotide against tumors of diverse histologic origins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206999

Depletion of Bcl-2 by an antisense oligonucleotide induces apoptosis accompanied by oxidation and externalization of phosphatidylserine in NCI-H226 lung carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206999

Angiostatin binds ATP synthase on the surface of human endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206999

Current targets for anticancer drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206999

In vivo formation of complex microvessels lined by human endothelial cells in an immunodeficient mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206999

Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206999

Effects of angiogenesis inhibitors on multistage carcinogenesis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206999

7 January 2021

Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206999

7 January 2021

Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206999

7 January 2021

Bcl-2 has differing effects on the sensitivity of breast cancer cells depending on the antineoplastic drug used.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206999

7 January 2021

Endothelin-1 protects ovarian carcinoma cells against paclitaxel-induced apoptosis: requirement for Akt activation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206999

7 January 2021

Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206999

7 January 2021

Chemosensitisation of malignant melanoma by BCL2 antisense therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206999

7 January 2021

Targeted drugs take centre stage at US cancer meeting

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206999

7 January 2021

Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206999

7 January 2021

The regulation of neovascularization of matrix metalloproteinases and their inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206999

7 January 2021

Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206999

7 January 2021

Bcl-2 and bcl-xL antisense oligonucleotides induce apoptosis in melanoma cells of different clinical stages

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206999

7 January 2021

Analysis of ribosyl-modified, mixed backbone analogs of a bcl-2/bcl-xL antisense oligonucleotide

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206999

7 January 2021

Endostatin: an endogenous inhibitor of angiogenesis and tumor growth

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206999

7 January 2021

Hypoxia upregulates Bcl-2 expression and suppresses interferon-gamma induced antiangiogenic activity in human tumor derived endothelial cells.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206999

7 January 2021

Identifiers

DOI

10.1038/SJ.ONC.1206999

1 reference

Dimensions Publication ID

22 September 2017

0 references

1 reference